my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults

Starting soon · Not applicable

Conditions studied: Sarcoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Acute Myeloid Leukemia, Aml, ALL, Medulloblastoma, Acute Lymphoblastic Leukemia ,Lymphomas

In brief

This study aims to design and test a novel, personalized digital intervention-my.naviGATE-for adolescent and young adults (AYA) with cancer. my.naviGATE is a mobile app that provides personalized survivorship education, access to virtual peer navigation, and responsive participant-reported outcomes (PROs).

Key facts

Study ID

NCT07516353

Run by

Dana-Farber Cancer Institute

People needed

143

Starts

2026-08-20

Expected to finish

2030-12-31

Last updated by the study team

2026-04-08

Who can join

Age: 15 and older, up to 24. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged 15-24 who are currently undergoing cancer treatment at one of the three participating sites: DFCI, CNH, or RPOCH.
• Patients must have initiated and be actively receiving cancer directed therapy for a newly diagnosed cancer.
• Patients must be actively receiving cancer directed therapy, between the time of diagnosis and end of therapy for the following diagnoses: 1) Sarcomas: including osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma; 2) Acute Myeloid Leukemia (AML); 3) Acute Lymphoblastic Leukemia/Lymphoma (ALL); 4) Hodgkin and mature B-cell Lymphomas; and 5) Medulloblastoma.
• Patients whose treatment includes alkylators, anthracyclines, and/or radiation.
• Inclusion of Children:
• This study is designed to keep AYAs aged 15-24 engaged in cancer survivorship care and therefore a subset of participants will be <18 years of age. The rationale for inclusion of children in this study is that AYA cancer survivors are particularly vulnerable to loss to follow-up and consequently lack of risk-based survivorship care, resulting in increased risk for preventable toxicity. Many existing interventions to improve engagement in survivorship screening and care are introduced after treatment completion and in long-term survivorship. Yet, for patients who are unaware of their late effect risks, and/or those who move frequently and are lost to follow-up, this may be too late. This study is designed to improve awareness of and engagement in risk-informed survivorship care for AYAs. This study presents no more than minimal risk to participants.

You may not qualify if…

• Patients who are unwilling to give informed consent or assent to participate will be excluded. For patients under 18, patients whose guardians do not give informed consent will be excluded.
• Patients with no chance of cure as identified by the AYA's physician, will be excluded given that issues of survivorship are not relevant and may be distressing to this population. Similarly, patients with relapsed or refractory disease will also be excluded.
• Patients who are non-English-speaking and -reading will be excluded as the digital tool is being developed initially in English.
• We will seek physician permission before offering enrollment to patients. If the provider team requests that the patient not be approached to participate, the patient will be excluded.

Where it is running

• Dana Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.